Roy Herbst, MD, PhD of Yale School of Medicine, New Haven, CT talks about pembrolizumab and the importance of the PD-L1 biomarker. Prof. Herbst explains that the biomarker does help discriminate patients who will benefit most from the drug. He further explains that patients should now be tested for PD-L1 at diagnosis and those who are PD-L1 positive will receive pembrolizumab and those who are PD-L1 negative will receive other treatment.
Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.
- Pembrolizumab and the significance of PD-L1 for lung cancer ( Download)
- How does PD-L1 impact treatment options for lung cancer ( Download)
- Explaining Immunotherapy, PD-L1 and PD-1 ( Download)
- Cancer immunotherapy | The PD-L1 pathway ( Download)
- The significance of PD-L1 expression in NSCLC ( Download)
- Dr. Joel Neal on Impact of PD-L1 Tests on Pembrolizumab, Nivolumab Efficacy in Frontline NSCLC ( Download)
- Outcomes of first-line pembrolizumab monotherapy for PD-L1–positive metastatic NSCLC ( Download)
- Antibiotics impact outcomes with pembrolizumab in NSCLC patients ( Download)
- Efficacy Of PDL1 Inhibitors & Immunotherapy In Lung Cancer | Dr. Suresh Babu M.C | Doctors' Circle ( Download)
- Dr. Brahmer Discusses Frontline Single-Agent Pembrolizumab in Lung Cancer ( Download)
- All you need to know about PD-L1 by Immunohistochemistry ( Download)
- The Future Role of PD-L1 Testing in Lung Cancer ( Download)
- Dr. Desai on Immunotherapy in Patients With NSCLC and Low PD-L1 Expression ( Download)
- Treating PD-L1-positive NSCLC with immunotherapy alone vs chemoimmunotherapy ( Download)
- PD-L1/PD-1 Pathway: A Security Checkpoint ( Download)
